Wegovy (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence
Novo Nordisk announced an update to the Singapore label for semaglutide, approved in Singapore as Wegovy® (semaglutide) injection, incorporating clinical evidence from the STEP UP trial in adults living with obesity without diabetes. In the trial, which evaluated a higher dose of semaglutide (7.2 mg), up to one in three participants receiving the higher dose achieved at least 25% weight loss over 72 weeks, while me…
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- NVONovo Nordisk A/S Named
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief

